European Commission Unveils Measures to Unleash the Potential of Health Data

European Commission Unveils Measures to Unleash the Potential of Health Data
July 7, 2022

The European Commission has presented its Proposal for a Regulation on the European Health Data Space (the “Proposal”). While it aims to strengthen the rights of individuals and unlock data’s potential for research purposes, it also adds complexity to an already extensive legal framework. Here is what you need to know:

In its 2020 Data Strategy, the European Commission outlined a plan to unlock the untapped potential of the EU data economy. It envisioned a single European data space comprising several sectoral data spaces in key areas. To realise this vision, the Commission has devised a multi-layered legal framework, which it has been gradually introducing since then. The Data Governance Act and the Data Act Proposal (currently under discussion) form the horizontal part of this framework. The draft proposal for the European Health Data Space Regulation, published in May 2022, is the first sectoral text to build on this horizontal framework.

The Proposal aims to ensure the free movement, sharing and reuse of health data for the benefit of patients, researchers and businesses alike. It sets standards for the processing of electronic health data for both primary use (for the provision of health services to individuals) and secondary use (for research, innovation, policy-making, statistics and protection against cross-border health threats). We list the main highlights below:

To whom does the draft apply?

The draft includes in its personal scope:

  • Electronic Health Record (EHR) systems and wellness application manufacturers and providers;
  • Controllers and processors who process the electronic health data of EU citizens or residents;
  • Controllers and processors established in a third country connected (or interoperable) with MyHealth@EU;  and,
  • Data users to whom electronic health data is provided by data holders in the Union.

All entities involved in the processing of health data or that may be in a position to use health data should follow these developments closely.

New rules for primary use

Chapter II of the Proposal outlines new rights and obligations for the main stakeholders (patients, health professionals, EHR system providers and the Member States) in this area:

  • For natural persons, the Proposal provides the right to free electronic access to their health data in a common European format. They will also have the right to rectification and to transfer their health data to third parties (portability).
  • Health professionals will have a corresponding right of access to the data of the persons under their treatment, including when they provide cross-border health services. However, they are obliged to register certain categories of health data in an electronic format.
  • To facilitate cross-border healthcare, the Proposal foresees that Member States will implement the MyHealth@EU platform to serve as the common infrastructure for the cross-border sharing of personal electronic health data and products. By 2025, the platform is expected to provide “ePrescriptions” for EU citizens to obtain medication in another EU country, as well as digital patient summaries that can be translated into all EU languages.
  • EHR systems marketed in the EU will conduct a conformity assessment and demonstrate compliance with specifications adopted by the Commission through implementing acts. The Commission will maintain a publicly accessible database on EHR systems.

Permit-based secondary use of electronic health data

To expand the reuse of health data, the Proposal provides a permit-based system. The Member States will designate one or more health data access bodies that will cooperate with the data protection authorities. Data holders will be obliged to transfer certain categories of electronic health data to the health data access bodies, which will be tasked with reviewing data access requests from data users who wish to re-use health data for secondary purposes.

The permit is granted on the basis of an application that must include details on a number of points, such as a description of the data requested, the reasons for the access requested, the intended uses, the safeguards, the duration and whether the data is to be provided in an anonymised or aggregated format. The Proposal specifies for which purposes and under which conditions access can be granted, but also which secondary uses are prohibited.

Supervision and enforcement

The European Commission will establish a “European Digital and Health Data Board” composed of representatives of the competent authorities of all the Member States and the Commission. The Board will support the Regulation’s implementation and cooperation between the competent authorities.

As far as enforcement is concerned, it will be left to the Member States to establish “effective, proportionate and dissuasive” penalties for infringements.

Interaction with existing and imminent laws

The Proposal is without prejudice to existing laws, such as the General Data Protection Regulation (GDPR) and Data Governance Act, as well as laws that have not yet come into force, such as the proposed Data Act and AI Act. The Proposal seeks to build on these laws – but unlike them, it focuses exclusively on health data. The Proposal explicitly addresses the interplay with the GDPR, providing the legal basis for permit-based processing, and foreseeing the GDPR roles of different stakeholders. Nevertheless, it will inevitably lead to legal uncertainties as the EU legal framework for data sharing becomes more complex.

The Proposal is a lengthy document (122 pages!) and the description above only gives a broad outline. If you would like more details or to discuss the possible implications for your organisation, then please do not hesitate to contact our team at ALTIUS.

Written by

  • Jan Clinck

    Counsel

Recommended articles

March 17, 2025

The new Belgian government’s public health policy: 10 key take-aways for pharma policy

The new Belgian federal government has outlined its vision for public health in a policy paper under the slogan “More money for health, more health for our money”. Public health is a high-priority sector with a significant budget, and the policy paper introduces several key measures that will shape the pharmaceutical industry in the coming years. For pharma companies operating in Belgium, these developments bring both new regulatory challenges and strategic opportunities. Here is a focused analysis of ten key changes and their potential impact on the pharma industry.

Read on
March 13, 2025

CJEU’s DocMorris Ruling: where is the line for pharmaceutical advertising?

The intersection of pharmaceutical advertising, consumer protection, and internal market freedoms remains a complex legal battleground within the EU. In Apothekerkammer Nordrhein v. DocMorris NV (C-517/23), the Court of Justice of the European Union (CJEU) revisited the meaning of ‘advertising of medicinal products’, clarifying how far national restrictions on pharmaceutical advertisements can go under EU pharmaceutical law and internal market principles.

Read on
February 12, 2025

New year, new policy: CPVO updates its public access to documents policy

The Community Plant Variety Office (CPVO) recently revised its public access to documents policy to align with the European Union (EU)’s evolving transparency standards. Effective since 15 January 2025, the new policy seeks to ensure broad access to all documents that the CPVO holds, while protecting private parties’ commercial interests. In particular, a system of prior confidentiality requests has been put in place for applicants of Community plant variety rights (CPVR).

Read on